# Developmental Funds

> **NIH NIH P30** · UNIVERSITY OF CHICAGO · 2021 · $434,458

## Abstract

ABSTRACT 
Over the past five years, Developmental Funds have been used to support Pilot Projects, recruitment of new 
investigators, and development of new Shared Resources and services to further UCCCC strategic goals, 
including a) Precision Medicine and the UCCCC Personalized Cancer Care Consortium (PCCC); b) Cancer 
Prevention and Population Medicine; and c) Cancer Survivorship, Outcomes, and Economics as well as 
interdisciplinary and interprogrammatic collaborations. From 2013-2016, a CCSG investment of $939,622 has 
yielded a remarkable return of $12,456,464 in peer-reviewed support, as well as publications and 
programmatic development. Support for four new investigators has contributed to enhancements of the 
Molecular Mechanisms of Cancer, Clinical and Experimental Therapeutics, and Cancer Prevention and Control 
Programs. Recruitments include: Megan McNerney, MD, PhD, a physician scientist who focuses on the 
genomics of therapy-related and de novo acute myeloid leukemias (AML), and molecular diagnostics; David 
VanderWeele, MD, PhD, who studies tumor heterogeneity, with a focus on genitourinary malignancies; Akash 
Patnaik, MD, PhD, who is a translational physician scientist working at the interface between laboratory-based 
investigations and early-phase clinical trials in prostate cancer; and Jane Churpek, MD, who is a clinician/ 
researcher who focuses on hereditary cancer susceptibility syndromes with an emphasis on hematological 
malignancies. Four new developing Shared Resources or new services were supported with CCSG 
Developmental Funds: the Human Imaging Research Office (HIRO), Imaging Chemistry Subcore within the 
Integrated Small Animal Imaging Research Resource, the development of CRISPR/Cas9 technology in the 
Transgenic Mouse and ES Cell Facility, and the Bioinformatics Core Facility, the latter is now proposed as a 
full Core. The developing Cores continue to grow and contribute to interdisciplinary research. 
Over the next grant period, we are requesting $300,000/year for: 1) recruitment of new investigators 
($100,000); 2) Program development/Program Pilot Projects ($100,000); and 3) development of new Shared 
Resources and the development of new services and integration of new technologies ($100,000). These funds 
will be used to further the three components of our Strategic Plan: 1) developing new biomarkers, novel 
treatments, and new interventions to prevent cancer; 2) efficiently integrating effective treatments and 
interventions into medical practice; and 3) assessing the impact of these new approaches on health outcomes, 
and addressing cancers relevant to our catchment area. Underpinning each of these initiatives is computation- 
based models for cancer research and care.

## Key facts

- **NIH application ID:** 10162532
- **Project number:** 5P30CA014599-46
- **Recipient organization:** UNIVERSITY OF CHICAGO
- **Principal Investigator:** KUNLE ODUNSI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $434,458
- **Award type:** 5
- **Project period:** 1997-09-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10162532

## Citation

> US National Institutes of Health, RePORTER application 10162532, Developmental Funds (5P30CA014599-46). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10162532. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*